Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
27.8% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
25.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
5.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Alpha and Omega Semiconductor
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Transition To Total Solutions Will Unlock High-Value Market Opportunities
Key Takeaways Transitioning to a total solutions provider enables market share growth, increased BOM content, and higher revenue and margin potential across multiple sectors. Expanding into AI, high-end smartphones, and emerging applications diversifies revenue streams, tapping into higher-value markets with improved margins.
View narrative
US$30.67
FV
17.6% undervalued
intrinsic discount
5.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
20 days ago
author updated this narrative
Delek US Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
Refinery Upgrades And Cost Cutting Will Drive Future Profitability
Key Takeaways Improved operational performance and asset swaps enhance refinery profitability and revenue growth, positively impacting earnings and net margins. Strategic expansions and cost reduction efforts boost cash flow and profitability, driving shareholder value and financial performance improvement.
View narrative
US$21.46
FV
3.6% undervalued
intrinsic discount
-3.84%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
20 days ago
author updated this narrative
Altice USA
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Expanding Fiber Networks And AI Will Build A Bright Future
Key Takeaways Altice USA's fiber network expansion and AI-driven efficiency strategies are poised to drive subscriber growth, reduce expenses, and enhance margins. By broadening its product offerings and targeting income-constrained consumers, Altice USA aims to unlock new revenue streams and improve customer loyalty.
View narrative
US$2.88
FV
28.9% undervalued
intrinsic discount
-2.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
20 days ago
author updated this narrative
Arcus Biosciences
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles
Key Takeaways Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market. Strong financial partnerships and a long cash runway ensure sustained R&D investment and potential earnings growth through strategic planning.
View narrative
US$28.18
FV
67.5% undervalued
intrinsic discount
30.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
20 days ago
author updated this narrative
Immunocore Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Key Takeaways Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK. Strong financial position and diverse clinical pipeline position Immunocore for future revenue growth and increased net margins.
View narrative
US$62.18
FV
48.7% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
20 days ago
author updated this narrative
NetScout Systems
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Investments In AI And Partnerships With Palo Alto Networks Will Strengthen Edge Cybersecurity Solutions
Key Takeaways Increased demand for service assurance and cybersecurity products, along with AI investments, could drive revenue growth and improve margins. Partnerships and strategic financial actions, like debt repayment and share buybacks, could enhance market presence and improve earnings per share.
View narrative
US$22.23
FV
1.3% undervalued
intrinsic discount
1.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
20 days ago
author updated this narrative
Global Net Lease
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Transition To Single-Tenant Net Lease Will Reduce Leverage And Simplify Operations
Key Takeaways Sale of noncore properties and focus on single-tenant strategy reduce leverage and operational complexity, enhancing earnings potential. Share repurchase, increased occupancy, and dividend reduction support EPS growth, liquidity, and revenue stability.
View narrative
US$9.42
FV
21.3% undervalued
intrinsic discount
-17.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
20 days ago
author updated this narrative
6855
Ascentage Pharma Group International
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Key Takeaways Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth. Successful NASDAQ IPO and promising registrational trials position the company to accelerate pipeline development, enhancing future earnings potential.
View narrative
HK$69.92
FV
12.0% overvalued
intrinsic discount
19.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
20 days ago
author updated this narrative
Baytex Energy
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Operational Gains In Eagle Ford And Pembina Duvernay May Lower Costs, But OPEC Actions And Tariffs Could Affect Future Revenues
Key Takeaways Efficiency improvements in key plays are poised to enhance capital costs, production performance, and positively impact revenue and net margins. Sustainable reserve growth supports future production, potentially increasing revenue and long-term valuation through strategic shareholder returns and development plans.
View narrative
CA$3.95
FV
30.6% undervalued
intrinsic discount
-3.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
41
users have followed this narrative
20 days ago
author updated this narrative
Value any company in seconds
Popular companies